Table 1 Characteristics of patients at baseline in 2019–2020: sex, age, CF genotype and CFTR modulators

F

27

1717-1G- > A/1717-1G- > A

F

25

F508del/F508del

Lumacaftor/Ivacaftor

F

18

F508del/F508del

Lumacaftor/Ivacaftor

F

9

F508del/R1066H

F

31

2183AA > G/ 3276C > A

M

15

F508del/F508del

Lumacaftor/Ivacaftor

M

20

F508del/3002_3003delTG

F

24

F508del/3849 + 10kbC > T

M

8

1584 + 18672A > G/F508del

M

27

N1303K/G542X

F

14

F508del/F508del

Lumacaftor/Ivacaftor

F

17

G542X/I507del

F

25

F508del/F508del

Lumacaftor/Ivacaftor

F

16

F508del/621 + 1G- > T

F

20

F508del/2368-69del11

M

42

F508del/N1303K

M

11

F508del/F508del

M

24

F508del/R1162X

F

10

I507del/1677delTA

M

17

F508del/F508del

Lumacaftor/Ivacaftor

M

32

F508del/G542X

M

36

F508del/I507del

F

29

F508del/G551D

Ivacaftor

F

30

F508del/CFTRdel17a-18

Elexacaftor/Tezacaftor/ Ivacaftor

F

10

F508del/621 + G

M

10

F508del/621 + G

M

34

F508del/CFTRdel17a-18

F

23

F508del/F508del

Lumacaftor/Ivacaftor

F

21

F508del/G1298X

M

33

223C > T/UN

M

22

1717-G > A/R1162X

F

33

F508del/N1303K

F

33

F508del/T338I

F

17

F508del/S466X-R1070Q